최소 단어 이상 선택하여야 합니다.
최대 10 단어까지만 선택 가능합니다.
다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
NTIS 바로가기Korean journal of microbiology = 미생물학회지, v.49 no.3, 2013년, pp.221 - 227
Human immunodeficiency virus (HIV), hepatitis B virus (HBV), and hepatitis C virus (HCV) cause viral infections that lead to chronic diseases. When they invade human body, virus specific T cells play an important role in antiviral effector functions including killing virus-infected cells and helping...
* AI 자동 식별 결과로 적합하지 않은 문장이 있을 수 있으니, 이용에 유의하시기 바랍니다.
핵심어 | 질문 | 논문에서 추출한 답변 |
---|---|---|
PD-1과 CTLA-4는 구조적으로 어디에 속합니까? | T림프구 수용체(T cell receptor; TCR)와 펩타이드를 제시하는 주조직 적합성 복합체(peptide/MHC)의 결합이 첫번째 신호이며, 공동자극분자(costimulatory molecules)인 CD28과 항원제시세포(Antigen presenting cells)의 B7 (B7-1 또는 B7-2) 결합이 두번째 신호이다. PD-1과 CTLA-4는 구조적으로 CD28 family에 속하며 면역조절(immune regulation)에서 중요한 역할을 하는 억제수용체(inhibitory receptor)로 특히 바이러스 감염의 만성화와 PD-1 또는 CTLA-4의 지속적 발현이 깊은 상관관계를 가짐이 보고되었다(Freeman et al., 2006; Golden-Mason et al. | |
FoxP3는 무엇이며 무엇을 조절합니까? | FoxP3 (forkhead box P3)는 조절 T림프구(Treg)의 발현에 필수적인 전사인자로 FoxP3+ Tregs은 활성화된 T림프구의 기능을 직접적으로 억제하거나 IL-10 또는 TGF-β와 같은 항염증(anti-inflammatory) 싸이토카인을 분비함으로써 과도한 면역반응을 제어할 수 있다(Wan et al., 2010). | |
PD-1과 CTLA-4 수용체는 무엇과 결합하여 T 림프구의 활성을 억제합니까? | , 2007). PD-1은 항원제시세포가 발현하는 PD-L1/PD-L2와 결합하며, CTLA-4는 CD28과 경쟁적으로 B7-1 (또는 B7-2)과 결합 함으로써 두 수용체 모두 T림프구의 활성을 억제하는 기능을 가진다(Fife and Bluestone, 2008). |
Alvarez, D. 2004. Clinical perspective: Battling hepatitis C in our HIV-infected patients. Res. Initiat. Treat. Action 10, 26-27.
Azuma, T., Takahashi, T., Kunisato, A., Kitamura, T., and Hirai, H. 2003. Human CD4+ CD25+ regulatory T cells suppress NKT cell functions. Cancer Res. 63, 4516?4520.
Barber, D.L., Wherry, E.J., Masopust, D., Zhu, B., Allison, J.P., Sharpe, A.H., Freeman, G.J., and Ahmed, R. 2006. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature 439, 682?687.
Bertoletti, A. and Naoumov, N.V. 2003. Translation of immunological knowledge into better treatments of chronic hepatitis B. J. Hepatol. 39, 115-124.
Billerbeck, E., Bottler, T., and Thimme, R. 2007. Regulatory T cells in viral hepatitis. World J. Gastroenterol. 13, 4858-4864.
Boulassel, M.R., Delwart, M.R., and Sepulveda, H. 2006. Upregulation of PD-1 expression on HIV-specific CD8+ T cells leads to reversible immune dysfunction. Nat. Med. 12, 1198-1202.
Brunkow, M.E., Jeffery, E.W., Hjerrild, K.A., Paeper, B., Clark, L.B., Yasayko, S.A., Wilkinson, J.E., Galas, D., Ziegler, S.F., and Ramsdell, F. 2001. Disruption of a new forkhead/winged-helix protein, scurfin, results in the fatal lymphoproliferative disorder of the scurfy mouse. Nat. Genet. 27, 68-73.
Cao, J., Zhang, L., Huang, S., Chen, P., Zou, L., Chen, H., Xiang, Y., Lai, X., and Ren, G. 2011. Aberrant production of soluble co-stimulatory molecules CTLA-4 and CD28 in patients with chronic hepatitis B. Microb. Pathog. 51, 262-267.
Card, C.M., McLaren, P.J., Wachihi, C., Kimani, J., Plummer, F.A., and Fowke, K.R. 2009. Decreased immune activation in resistance to HIV-1 infection is associated with an elevated frequency of CD4(+)CD25(+)FOXP3(+) regulatory T cells. J. Infect. Dis. 199, 1318-1322.
Chae, H.B., Kim, J.H., Kim, J.K., and Yim, H.J. 2009, Current status of liver diseases in Korea: hepatitis B. Korean J. Hepatol. 15, S13-24.
Chen, L. 2004. Co-inhibitory molecules of the B7-CD28 family in the control of T-cell immunity. Nat. Rev. Immunol. 4, 336-347.
Chen, Y.Q. and Shi, H.Z. 2006. CD28/CTLA-4--CD80/CD86 and ICOS--B7RP-1 costimulatory pathway in bronchial asthma. Allergy 61, 15?26.
Day, C.L., Kaufmann, D.E., Kiepiela, P., Brown, J.A., Moodley, E.S., Reddy, S., Mackey, E.W., Miller, J.D., Leslie, A.J., and DePierres, C. 2006. PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature 443, 350?354.
Ebinuma, H., Nakamoto, N., Li, Y., Price, D.A., Gostick, E., Levine, B.L., Tobias, J., Kwok, W.W., and Chang, K.M. 2008. Identification and in vitro expansion of functional antigen-specific CD25+ FoxP3+ regulatory T cells in hepatitis C virus infection. J. Virol. 82, 5043-5053.
Evans, A., Riva, A., Cooksley, H., Phillips, S., Puranik, S., Nathwani, A., Brett, S., Chokshi, S., and Naoumov, N.V. 2008. Programmed death 1 expression during antiviral treatment of chronic hepatitis B: Impact of hepatitis B e-antigen seroconversion. Hepatology 48, 759?769.
Fife, B.T. and Bluestone, J.A. 2008. Control of peripheral T-cell tolerance and autoimmunity via the CTLA-4 and PD-1 pathways. Immunol. Rev. 224, 166-182.
Freeman, G.J., Wherry, E.J., Ahmed, R., and Sharpe, A.H. 2006. Reinvigorating exhausted HIV-specific T cells via PD-1-PD-1 ligand blockade. J. Exp. Med. 203, 2223-2227.
Gardiner, D., Lalezari, J., Lawitz, E., DiMicco, M., Ghalib, R., Reddy, K.R., Chang, K.M., Sulkowski, M., Marro, S.O., Anderson, J., and et al. 2013. A randomized, double-blind, placebo-controlled assessment of BMS-936558, a fully human monoclonal antibody to programmed death-1 (PD-1), in patients with chronic hepatitis C virus infection. PLoS One 22, 8(5):e63818.
Golden-Mason, L., Palmer, B., Klarquist, J., Mengshol, J.A., and Castelblanco, N. 2007. Upregulation of PD-1 expression on circulating and intrahepatic hepatitis C virus-specific CD8+ T cells associated with reversible immune dysfunction. J. Virol. 81, 9249-9258.
Kahn, J.O. and Walker, B.D. 1998. Acute human immunodeficiency virus type 1 infection. N. Engl. J. Med. 331, 33-39.
Kim, Y.S., Pai, C.H., Chi, H.S., Kim, D.W., Min, Y.I., and Ahn, Y.O. 1992. Prevalence of hepatitis C virus antibody among Korean adults. J. Korean Med. Sci. 7, 333-336.
Lauer, G.M. and Walker, B.D. 2001. Hepatitis C virus infection. New Engl. J. Med. 345, 41-52.
Lee, C.K., Han, K.H., Suh, J.H., Cho, Y.S., Won, S.Y., Chon, C.Y., Moon, Y.M., and Park, I.S. 2005. HBV-specific CD8+ T cells for sustained HBeAg seroconversion after lamivudine therapy. Korean J. Hepatol. 11, 34-42.
Lee, K.S. and Kim, D.J. 2012. Korean association for the study of the liver. Clin. Mol. Hepatol. 2, 109-162.
Liang, T.J., Rehermann, B., Seeff, L.B., and Hoofnagle, J.H. 2000. Pathogenesis, natural istory, treatment and prevention of hepatitis C. Ann. Intern. Med. 32, 296-305.
Li, S., Gowans, E.J., Chougnet, C., Plebanski, M., and Dittmer, U. 2008. Natural regulatory T cells and persistent viral infection. J. Virol. 82, 21-30.
Linsley, P.S., Greene, J.L., Tan, P., Bradshaw, J., Ledbetter, J.A., Anasetti, C., and Damle, N.K. 1992. Coexpression and functional cooperation of CTLA-4 and CD28 on activated T lymphocytes. J. Exp. Med. 176, 1595-1604.
Lim, H.W., Hillsamer, P., Banham, A.H., and Kim, C.H. 2005. Cutting edge: direct suppression of B cells by CD4+CD25+ regulatory T cells. J. Immunol. 175, 4180-4183.
McHutchison, J.G., Gordon, S.C., Schiff, E.R., Shiffman, M.L., Lee, W.M., Rustigi, V.K., Goodman, Z.D., Ling, M.H., Cort, S., and Albrect, J.K. 1998. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N. Eng. J. Med. 339, 1485-1492.
Mills, K.H. and McGuirk, P. 2004. Antigen-specific regulatory T cells - their induction and role in infection. Semin. Immunol. 16, 107-117.
Muhlbauer, M., Fleck, M., Schutz, C., Weiss, T., Froh, M., Blank, C., Scholmerich, J., and Hellerbrand, C. 2006. PD-L1 is induced in hepatocytes by viral infection and by interferon-alpha and -gamma and mediates T cell apoptosis. J. Hepatol. 45, 520-528.
Nakamoto, N., Cho, H., Shaked, A., Olthoff, K., Valiga, M.E., Kaminski, M., Gostick, E., Price, D.A., Freeman, G.J., Wherry, E.J., and et al. 2009. Synergistic reversal of intrahepatic HCV-specific CD8 T cell exhaustion by combined PD-1/CTLA-4 blockade. PLoS Pathog. 5, e1000313.
Nakamoto, N., Kaplan, D.E., Coleclough, J., Li, Y., Valiga, M.E., Kaminski, M., Shaked, A., Olthoff, K., Gostick, E., Price, D.A., and et al. 2008. Functional restoration of HCV-specific CD8 T cells by PD-1 blockade is defined by PD-1 expression and compartmentalization. Gastroenterology 134, 1927?1937.
Ohkura, N. and Sakaguchi, S. 2010. Regulatory T cells: roles of T cell receptor for their development and function. Semin Immunopathol. 32, 95?106.
Oh, M.D. and Choe, K.W. 1999. Epidemiology of HIV infection in the republic of Korea. J. Korean Med. Sci. 14, 469-474.
Operskalski, E.A. and Kovacs, A. 2011, HIV/HCV co-infection: Pathogenesis, clinical complications, treatment, and new therapeutic technologies. Curr. HIV/AIDS Rep. 8, 12-22.
Pagliaro, L., Craxi, A., Cammaa, C., Tine, F., Di Marco, V., and Almasio, P. 1994. Interferon-alpha for chronic hepatitis C: an analysis of pretreatment clinical predictors of response. Hepatology 19, 820?828.
Palella, F.J., Delaney, K.M., Moorman, A.C., Loveless, M.O., Fuhrer, J., Satten, G.A., Aschman, D.J., and Holmberg, S.D. 1998. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N. Engl. J. Med. 338, 853-860.
Peng, G., Li, S., Wu, W., Tan, X., Chen, Y., and Chen, Z. 2008. PD-1 upregulation is associated with HBV-specific T cell dysfunction in chronic hepatitis B patients. Mol. Immunol. 45, 963-970.
Probst-Kepper, M., Balling, R., and Buer, J. 2010. FOXP3: required but not sufficient. the role of GARP (LRRC32) as a safeguard of the regulatory phenotype. Curr. Mol. Med. 10, 533-539.
Romagnani, C., Della Chiesa, M., Kohler, S., Moewes, B., Radbruch, A., Moretta, L., Moretta, A., and Thiel, A. 2005. Activation of human NK cells by plasmacytoid dendritic cells and its modulation by CD4+ T helper cells and CD4+CD25hi T regulatory cells. Eur. J. Immunol. 35, 2452-2458.
Rouse, B.T., Sarangi, P.P., and Suvas, S. 2006. Regulatory T cells in virus infections. Immunol. Rev. 212, 272-286.
Sakaguchi, S. 2005. Naturally arising Foxp3-expressing CD25+CD4+ regulatory T cells in immunological tolerance to self and nonself. Nat. Immunol. 6, 345-352.
Sheppard, K.A., Fitz, L.J., Lee, J.M., Benander, C., George, J.A., Wooters, J., Qiu, Y., Jussif, J.M., Carter, L.L., Wood, C.R., and Chaudhary, D. 2004. PD-1 inhibits T-cell receptor induced phosphorylation of the ZAP70/CD3zeta signalosome and downstream signaling to PKCtheta. FEBS Lett. 3, 37?41.
Stamper, C.C., Zhang, Y., Tobin, J.F., Erbe, D.V., Ikemizu, S., Davis, S.J., Stahl, M.L., Seehra, J., Somers, W.S., and Mosyak, L. 2001, Crystal structure of the B7-1/CTLA-4 complex that inhibits human immune responses. Nature, 410, 608?611.
Stoop, J.N., Baan, C.C., van der Laan, L.J., Kuipers, E.J., Kusters, J.G., and Janssen, H.L. 2005. Regulatory T cells contribute to the impaired immune response in patients with chronic hepatitis B virus infection. Hepatology 41, 771?777.
Suchard, M.S., Mayne, E., Green, V.A., Shalekoff, S., Donninger, S.L., Stevens, W.S., Gray, C.M., and Tiemessen, C.T. 2010. FOXP3 expression is upregulated in CD4T cells in progressive HIV-1 infection and is a marker of disease severity. PLoS One 5, e11762.
Teoh, N.C. and and Farrell, G.C. 2004. Management of chronic hepatitis C virus infection: a new era of disease conrol. Intern. Med. J. 34, 324-337.
Tone, Y., Furuuchi, K., Kojima, Y., Tykocinski, M.L., Greene, M.I., and Tone, M. 2008. Smad3 and NFAT cooperate to induce Foxp3 expression through its enhancer. Nat. Immunol. 9, 194-202.
Trautmann, L., Janbazian, L., Chomont, N., Said, E.A., Wang, G., Gimmig, S., Bessette, B., Boulassel, M.R., Delwart, E., Sepulveda, H., and et al. 2006. Upregulation of PD-1 expression on HIV-specific CD8+ T cells leads to reversible immune dysfunction. Nat. Med. 12, 1198-1202.
Leng, Q., Bentwich, Z., Magen, E., Kalinkovich, A., and Borkow, G. 2002. CTLA-4 upregulation during HIV infection: association with anergy and possible target for therapeutic intervention. AIDS 16, 519?529.
Trzonkowski, P., Szmit, E., Mysliwska, J., Dobyszuk, A., and Mysliwski, A. 2004. CD4+CD25+ T regulatory cells inhibit cytotoxic activity of T CD8+ and NK lymphocytes in the direct cell-to-cell interaction. Clin. Immunol. 112, 258-267.
Vigouroux, S., Yvon, E., Biagi, E., and Brenner, M.K. 2004. Antigen-induced regulatory T cells. Blood 104, 26?33.
Wan, Y.Y. 2010. Regulatory T cells: immune suppression and beyond. Cell Mol. Immunol. 7, 204-210.
Wenjin, Z., Chuanhui, P., Yunle, W., Lateef, S.A., and Shusen, Z. 2012. Longitudinal fluctuations in PD1 and PD-L1 expression in association with changes in anti-viral immune response in chronic hepatitis B. BMC Gastroenterol. 12, 109?115.
Yim, H.J. and Lok, A.S. 2006. Natural history of chronic hepatitis B virus infection: what we knew in 1981 and what we know in 2005. Hepatology 43, S173?181.
Zaunders, J.J., Munier, M.L., Kaufmann, D.E., Suzuki, K., Brereton, C., Sasson, S.C., Seddiki, N., Koelsch, K., and Landay, A. 2006. Infection of CD127_(interleukin-7 receptor_) CD4_ cells and overexpression of CTLA-4 are linked to loss of antigen-specific CD4 T cells during primary human immunodeficiency virus type 1 infection. J. Virol. 80, 10162-10172.
*원문 PDF 파일 및 링크정보가 존재하지 않을 경우 KISTI DDS 시스템에서 제공하는 원문복사서비스를 사용할 수 있습니다.
출판사/학술단체 등이 한시적으로 특별한 프로모션 또는 일정기간 경과 후 접근을 허용하여, 출판사/학술단체 등의 사이트에서 이용 가능한 논문
※ AI-Helper는 부적절한 답변을 할 수 있습니다.